CN114081939A - 一种抗菌肽Cbf-14水凝胶及其制备方法和应用 - Google Patents
一种抗菌肽Cbf-14水凝胶及其制备方法和应用 Download PDFInfo
- Publication number
- CN114081939A CN114081939A CN202111409344.4A CN202111409344A CN114081939A CN 114081939 A CN114081939 A CN 114081939A CN 202111409344 A CN202111409344 A CN 202111409344A CN 114081939 A CN114081939 A CN 114081939A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- cbf
- polypeptide
- mass
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 69
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229920001184 polypeptide Polymers 0.000 claims abstract description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 27
- 229920000609 methyl cellulose Polymers 0.000 claims abstract description 19
- 239000001923 methylcellulose Substances 0.000 claims abstract description 19
- 235000010981 methylcellulose Nutrition 0.000 claims abstract description 19
- 239000012153 distilled water Substances 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract 2
- 239000000499 gel Substances 0.000 claims description 29
- 235000011187 glycerol Nutrition 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 15
- 239000003906 humectant Substances 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 230000008961 swelling Effects 0.000 claims description 12
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 11
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 11
- 206010052428 Wound Diseases 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 6
- 230000001580 bacterial effect Effects 0.000 abstract description 6
- 241000192125 Firmicutes Species 0.000 abstract 1
- 244000000010 microbial pathogen Species 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 28
- 241000700159 Rattus Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 229960003128 mupirocin Drugs 0.000 description 4
- 229930187697 mupirocin Natural products 0.000 description 4
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000272081 Bungarus fasciatus Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101150004219 MCR1 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000018655 severe necrosis Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 239000004520 water soluble gel Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种抗菌肽Cbf‑14水凝胶及其制备方法和应用,上述水凝胶包括以下质量百分含量的材料:多肽Cbf‑14 0.5%~2.0%、甲基纤维素1.0%~2.0%、丙三醇10.0%~15.0%、余量的蒸馏水。本发明所述的抗菌水凝胶对革兰阳性细菌、革兰阴性细菌等病原微生物菌均具有良好的抗菌活性,可有效降低大鼠皮肤伤口处的细菌载量,促进皮肤伤口愈合。本抗菌肽Cbf‑14水凝胶具有独特的制备工艺及便捷的给药方式,具有广泛的应用前景。
Description
技术领域
本发明涉及一种抗菌水凝胶及其制备方法和应用,具体涉及一种抗菌肽Cbf-14的水凝胶的制备方法及应用。
背景技术
水凝胶是一种三维交联的网状高分子材料,以水为分散介质,其亲水残基与水分子结合将水分子连结在网状内部,疏水残基遇水发生膨胀,这一特点使其在遇水溶胀之后可保持其原有结构而不被溶解。由于水凝胶具有良好的生物相容性以及生物安全性能,在生物酶的固定、组织工程、药物输送等领域被广泛应用,同时在环境卫生、记忆开关元件、化妆品以及食品工业等非医学领域也具有非常广阔的应用前景。
多肽Cbf-14是本实验室从金环蛇多肽BF-30的基础上设计改造衍生而来的含有14个氨基酸的阳离子多肽,其氨基酸序列为RLLRKFFRKLKKSV,具有抗耐药性病原菌感染的功效(该技术记载在中国专利ZL201611120800.2中)。多肽由于本身为机体防御的非特异性屏障,并且具有分子量小、热稳定性能强、抗菌谱广、免疫原力低的特点,相比较于化学凝胶剂更加安全、低毒、高效、广谱。但是目前缺少能进一步降低毒性的外用剂型。
发明内容
发明目的:本发明的目的在于提供一种抗菌肽Cbf-14水凝胶(Cbf-14 Gel),该制剂可抗菌并促进皮肤伤口愈合。本发明的另一个目的是提供该水凝胶的制备方法。本发明还有一个目的是提供抗菌肽Cbf-14水凝胶在制备创伤药物中的应用。
技术方案:本发明所述的抗菌肽Cbf-14的水凝胶,该水凝胶由以下质量百分含量的原材料制成:
多肽Cbf-14 0.5%~2.0%、凝胶基质1.0%~2.0%、保湿剂5.0%~15.0%、余量为蒸馏水。
该水凝胶由以下质量百分含量的原材料制成:
多肽Cbf-14 1.0%~2.0%、凝胶基质1.5%~2.0%、保湿剂8.0%~12.0%、余量为蒸馏水。
凝胶基质为甲基纤维素、羟乙基纤维素、壳聚糖、海藻酸钠、卡波姆中的一种或几种。
所述的水凝胶,以水凝胶原料的总量100.0%计算,凝胶基质由以下质量百分组分的成分组成:甲基纤维素2.0%~3.0%。
所述的水凝胶,保湿剂为甘油、丙二醇中的一种或几种。
所述的水凝胶,以水凝胶原料总量的100.0%计,保湿剂由以下质量百分含量的成分组成:甘油8.0%~10.0%。
所述水凝胶的制备方法,具体操作步骤如下:
(1)将甲基纤维素加蒸馏水混合,室温静置溶胀;
(2)将多肽Cbf-14溶解,过滤除菌;
(3)加入甘油搅拌溶解;
(4)将上述各组分混合均匀,静置溶胀,离心去除气泡即得抗菌肽Cbf-14水凝胶。
所述的水凝胶在制备创伤伤口产品中的应用。
所述的水凝胶在制备创伤药物中的应用。
本发明所述凝胶剂的制备方法,具体实施方式见附图1。
本发明提供的水凝胶是以多肽Cbf-14为核心抑菌组分,是针对细菌自身(质膜破坏/耐药基因结合)和宿主防御体系(免疫调控通路)多靶点对抗耐药菌活性和机制进行研发的I类新药品种。对多种耐药菌(包括携带ndm-1和mcr-1的超级细菌)的MIC低、杀菌速度快,且溶血性和细胞毒性低,靶点明确,同时具有抗真菌活性。水凝胶pH在7.0左右,黏度适中,在中性体系下有利于多肽Cbf-14保持良好的抗菌活性,能够发挥其广谱、高效抗菌功能。甲基纤维素具有优良的润湿性、分散性、粘接性、增稠性、乳化性、保水性和成膜性,以及对油脂的不透性。在医药、化工等领域都有重要意义。甘油具有低挥发性,可保持凝胶水分不流失。
有益效果:本发明核心抑菌组分为多肽Cbf-14,低毒,但不可避免有一定的毒副作用,我们经过大量制剂和工艺的筛选,将多肽Cbf-14制成水凝胶制剂,最大程度的降低其透过皮肤进入全身血液循环的可能,提高了生物安全性,降低了产品的毒副作用,同时保留其广谱、高效、稳定的抗菌功能。并且,所述多肽Cbf-14制成水凝胶的制备工艺简单,易行,为后续进行大规模生产奠定了基础。
附图说明
图1是抗菌肽Cbf-14水凝胶制剂工艺流程图;
图2是保湿剂种类对空白凝胶失水率的影响;
图3是甘油含量对空白凝胶失水率的影响;
图4是制备得到的抗菌肽Cbf-14水凝胶实物图;
图5是抗菌肽Cbf-14水凝胶扫描电镜图;
图6是单位面积24小时内药物的累计经皮透过量(n=3);
图7是药物在角质层样品(A)和剩余皮肤层样品(B)中的滞留量(n=3);
图8是抗菌肽Cbf-14水凝胶对金黄色葡萄球菌(临床分离株)感染的大鼠皮肤伤口的治疗作用;(A)10天内伤口的愈合情况图片;(B)A图对应的量化图;
图9是金黄色葡萄球菌(临床分离株)感染大鼠皮肤创面经抗菌肽Cbf-14水凝胶治疗6天后的细菌载量;与模型组比较,*p<0.05,**p<0.01,***p<0.001;
图10是金黄色葡萄球菌(临床分离株)感染大鼠皮肤创面经抗菌肽Cbf-14水凝胶治疗后的H&E染色结果。
具体实施方式
下列实施例中的“%”均为质量百分含量。
实施例1:
实施例1对抗菌肽Cbf-14水凝胶成胶基质的筛选进行公开。
常用的水溶性凝胶基质包括卡波姆、泊洛沙姆、纤维素类凝胶基质等,选择0.5%的卡波姆、4.0%的羧甲基纤维素钠、4.0%的羟乙基纤维素以及2.0%的甲基纤维素作为凝胶基质,制备凝胶基质与水混合形成的凝胶,并从外观性状、均一性、涂展性以及粘稠度进行评价以确定凝胶基质,具体结果见表1。
表1.多肽凝胶空白基质筛选考察结果
由表1结果可知,选择2.0%质量浓度的甲基纤维素可以形成质量较好的凝胶。
实施例2:
实施例2对抗菌肽Cbt-14水凝胶保湿剂的筛选进行公开。
选择甘油以及丙二醇进行保湿剂的筛选,分别加入不同的保湿剂、甲基纤维素以及蒸馏水进行凝胶的制备。对制备得到的凝胶进行失水率测定,并对其初步稳定性(离心稳定性、低温稳定性、耐热稳定性)进行评估。具体保湿剂的添加、分组情况以及实验结果见表2,不同保湿剂制备得到的凝胶的终点失水率见图2。
表2.不同保湿剂对制备凝胶的影响
由表2结果可知,选择甘油作为凝胶中的保湿剂有助于降低失水率,减少水分的流失,接下来对保湿剂用量进行进一步筛选,选择质量浓度为2.5%、5.0%、10.0%、15.0%的甘油进行凝胶的制备,并按照前述标准进行评价。具体制备所得的实验结果见表3,不同用量的甘油制备所得到的凝胶的终点失水率见图3。
表3.甘油用量对制备凝胶的影响
由表3结果可知,当甘油用量在10.0%以及15.0%时,都可以有效降低终点失水率,结合具体原材料的价格控制范围,因此最终确定甘油用量为10.0%。
实施例3:
配制含有下列质量百分含量原料的抗菌肽Cbf-14水凝胶:多肽Cbf-14 0.5%,甘油10.0%,甲基纤维素2.0%,蒸馏水补足余量。
含抗菌肽Cbf-14水凝胶的制备方法,包括以下步骤:首先将甲基纤维素加蒸馏水混合,室温静置溶胀;将多肽Cbf-14溶解,经过0.22μm滤膜过滤除菌;加入甘油搅拌溶解;将上述各组分混合均匀,静置溶胀,离心去除气泡即得抗菌肽Cbf-14水凝胶,抗菌肽Cbf-14水凝胶实物图见图4,扫描电镜图见图5。
实施例4
配制含有下列质量百分含量原料的抗菌肽Cbf-14水凝胶:多肽Cbf-14 1.0%,甘油10.0%,甲基纤维素2.0%,蒸馏水补足余量。
含抗菌肽Cbf-14水凝胶的制备方法,包括以下步骤:首先将甲基纤维素加蒸馏水混合,室温静置溶胀;将多肽Cbf-14溶解,经过0.22μm滤膜过滤除菌;加入甘油搅拌溶解;将上述各组分混合均匀,静置溶胀,离心去除气泡即得抗菌肽Cbf-14水凝胶。
实施例5
配制含有下列质量百分含量原料的抗菌肽Cbf-14水凝胶:多肽Cbf-14 2.0%,甘油10.0%,甲基纤维素2.0%,蒸馏水补足余量。
含抗菌肽Cbf-14水凝胶的制备方法,包括以下步骤:首先将甲基纤维素加蒸馏水混合,室温静置溶胀;将多肽Cbf-14溶解,经过0.22μm滤膜过滤除菌;加入甘油搅拌溶解;将上述各组分混合均匀,静置溶胀,离心去除气泡即得抗菌肽Cbf-14水凝胶。
对比例1
配制含有下列质量百分含量原料的空白水凝胶:甘油10.0%,甲基纤维素2.0%,蒸馏水补足余量。
不含多肽Cbf-14的空白水凝胶的制备方法,包括以下步骤:首先将甲基纤维素加蒸馏水混合,室温静置溶胀;加入甘油搅拌溶解;将上述各组分混合均匀,静置溶胀,离心去除气泡即得空白水凝胶。
实施例6
抗菌肽Cbf-14水凝胶透皮吸收实验
(1)大鼠离体皮肤制备
采用乌拉糖(6mL/kg,20%w/v,腹腔注射)将大鼠麻醉,立即用宠物剃毛刀剃去大鼠腹部皮肤上的长毛,再用剃须刀仔细除去短毛,剃毛过程尽量不损伤皮肤,若有皮肤损伤,将损伤皮肤进行标记;随后将大鼠脱颈处死,剥离腹部皮肤,避开已受损的皮肤,将腹部皮肤剪成适当大小。将取下的大鼠腹部皮肤平铺并且固定于木板上,使角质层朝下,用眼用手术小剪刀剔除皮下脂肪组织及结缔组织,并且不损伤皮肤。以扩散池面积为大小标准,每块皮肤分成四小块,取每块皮肤中的一小块组成一个组,共四个组,密封好后放-70℃冰箱,可放置1~2个月。
(2)经皮透过实验
采用Franz扩散池(池体积6.5mL,有效扩散面积2.2cm2)考察制剂中药物的体外经皮透过量。取解冻后的鼠皮,将皮肤覆盖在扩散池上,使角质层朝上,置于透皮吸收扩散装置。供给池中加入0.25g制剂样品,接收池中加入6.5mL接收液(pH 7.4 PBS缓冲液),接收液与皮肤之间不得留有气泡,于32±0.5℃,300rpm持续搅拌下进行。分别于2、8、24h从接收池中取样1mL,同时向接收池中补加等量新鲜的接收液。样品在12000rpm的转速下离心5min,上清液进行HPLC色谱测定。
(3)皮肤角质层和剩余层的分离处理
经皮透过实验后,将扩散池有效扩散面积部分的大鼠皮肤剪下来。用棉签轻轻将皮肤表面的液体拭去。之后用医用胶带粘贴皮肤角质层一侧,弃去前两次粘贴的胶带,收集之后12次粘贴后的胶带置于塑料管中,此部分为角质层样品(SC)。之后,将胶带粘贴后的皮肤剪碎,置于塑料管中,此部分为表皮真皮样品(EP&ED)。SC样品和EP&ED样品分别加入甲醇7mL和2mL,静置浸泡20min,超声40min 2次。样品在12000rpm的转速下离心5min,上清液进行HPLC色谱测定。
具体实验结果见表4、表5以及附图6、7,可看出与对照组复方多粘菌素软膏(Polymyxin)和莫匹罗星软膏(Mupirocin)相比,抗菌肽Cbf-14水凝胶中主药Cbf-14的经皮透过量、角质层中滞留量以及活性表皮&真皮层中的滞留量均低于定量限。因此本实验结果表明,与两个对照制剂相比,抗菌肽Cbt-14水凝胶中主药Cbf-14较难进入皮肤或透过皮肤进入全身血液循环。
表4不同时间点单位面积药物的经皮透过量(n=3)
注:aND表示not detectable,即样品浓度在定量限之下;
b经皮透过量的单位为μg/cm2
表5单位面积24小时内药物在皮肤层中的滞留量(n=3)
注:aND表示not detectable,即样品浓度在定量限之下;
b滞留量的单位为μg/cm2
实施例6
抗菌肽Cbf-14水凝胶皮肤伤口抗感染模型
实验动物:SD大鼠,体重120±10g,雌雄各半。
实验分组:实验分为6组,分别为模型组(给与0.9%的生理盐水),实施例3、4、5对应的凝胶组别,对比例1对应的凝胶组别以及莫匹罗星软膏阳性对照组,每组SD大鼠数量均为12只,雌雄各半。
实验菌株:金黄色葡萄球菌临床分离株。
实验步骤:(1)菌液制备:将实验所用的细菌株从保藏于-20℃的甘油管中转接至营养琼脂斜面培养基上,37℃培养16~20h至长出适宜量菌苔,挑取少量菌体接种至含2ml的无菌营养肉汤培养基中,置37℃培养8h后的培养液用无菌MH肉汤培养基倍比稀释至107CFU/ml左右的菌悬液,备用。
(2)建立皮肤伤口模型:将SD大鼠进行麻醉处理,背部朝上妥善固定,手术区域进行脱毛处理,用碘酒对大鼠背部进行消毒处理,准备手术。在背部制造直径为2cm的圆形伤口,至肌筋膜深层部位,创建全层皮肤创伤模型。使用金黄色葡萄球菌(临床株)进行感染。
(3)给药:按照前述分组进行给药,给药剂量为0.1g,每日早晚各给药一次,连续给药5天。
(4)5天后,无菌取感染部位皮肤,按体积1∶10稀释并研磨匀浆,检测活菌并进行计数统计。取创口组织研究皮肤的修复情况,进行H&E染色。
如图8所示,10天后,实验组已经基本痊愈,创面上皮化,痂皮脱落,创面基本愈合,伤口处基本上完全被毛发覆盖,证明真皮层已基本恢复其功能;如图9所示,与模型组(使用生理盐水进行治疗)相比,每天给药抗菌肽Cbf-14水凝胶能够使大鼠皮肤表面金黄色葡萄球菌的浓度显著降低,并且高剂量水凝胶组别几乎可以达到与阳性药莫匹罗星软膏组相同的抗菌效果。说明抗菌肽Cbf-14水凝胶对金黄色葡萄球菌(临床株)所引起的伤口感染具有良好的治疗效果;如图10所示,对比例组可见重度坏死及结缔组织增生,伴有中度炎症与出血;模型组坏死程度显著重于对比例组,其余病变略轻于对比例组;实施例5组增生结缔组织面积小于对比例组,其余病变较对比例组无明显差异;整体而言,模型组恢复情况最差,阳性药组略好于模型组,实施例5组恢复情况最好,对比例组、实施例3、4组差异不明显。
Claims (9)
1.一种抗菌肽Cbf-14的水凝胶,其特征在于,该水凝胶由以下质量百分含量的原材料制成:
多肽Cbf-14 0.5%~2.0%、凝胶基质1.0%~2.0%、保湿剂5.0%~15.0%、余量为蒸馏水。
2.根据权利要求1所述的水凝胶,其特征在于,该水凝胶由以下质量百分含量的原材料制成:
多肽Cbf-14 1.0%~2.0%、凝胶基质1.5%~2.0%、保湿剂8.0%~12.0%、余量为蒸馏水。
3.根据权利要求1或2所述的水凝胶,其特征在于,凝胶基质为甲基纤维素、羟乙基纤维素、壳聚糖、海藻酸钠、卡波姆中的一种或几种。
4.根据权利要求3所述的水凝胶,其特征在于,以水凝胶原料的总量100.0%计算,凝胶基质由以下质量百分组分的成分组成:甲基纤维素2.0%~3.0%。
5.根据权利要求1或2所述的水凝胶,其特征在于,保湿剂为甘油、丙二醇中的一种或几种。
6.根据权利要求5所述的水凝胶,其特征在于,以水凝胶原料总量的100.0%计,保湿剂由以下质量百分含量的成分组成:甘油8.0%~10.0%。
7.权利要求1所述水凝胶的制备方法,其特征在于,具体操作步骤如下:
(1)将甲基纤维素加蒸馏水混合,室温静置溶胀;
(2)将多肽Cbf-14溶解,过滤除菌;
(3)加入甘油搅拌溶解;
(4)将上述各组分混合均匀,静置溶胀,离心去除气泡即得抗菌肽Cbf-14水凝胶。
8.权利要求1或2所述的水凝胶在制备创伤伤口产品中的应用。
9.权利要求1或2所述的水凝胶在制备创伤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111409344.4A CN114081939B (zh) | 2021-11-24 | 2021-11-24 | 一种抗菌肽Cbf-14水凝胶及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111409344.4A CN114081939B (zh) | 2021-11-24 | 2021-11-24 | 一种抗菌肽Cbf-14水凝胶及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114081939A true CN114081939A (zh) | 2022-02-25 |
CN114081939B CN114081939B (zh) | 2024-05-24 |
Family
ID=80304450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111409344.4A Active CN114081939B (zh) | 2021-11-24 | 2021-11-24 | 一种抗菌肽Cbf-14水凝胶及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114081939B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU903003D0 (en) * | 1990-05-11 | 1990-09-28 | Reanal Finomvegyszergyar | Process for the production of a medicative preparation |
KR20100026910A (ko) * | 2008-08-29 | 2010-03-10 | 한스바이오메드 주식회사 | 서방형 골다공증치료제를 담지한 골충진재 |
CN105031609A (zh) * | 2015-07-22 | 2015-11-11 | 中国药科大学 | 含抗菌肽Cbf-14的消毒剂及其制备和用途 |
CN105497872A (zh) * | 2015-12-23 | 2016-04-20 | 中国药科大学 | 多肽Cbf-14抗真菌感染的医药用途 |
CN106543271A (zh) * | 2016-12-08 | 2017-03-29 | 中国药科大学 | 抗耐药性感染多肽Cbf‑14‑2及其用途 |
CN110169949A (zh) * | 2019-07-01 | 2019-08-27 | 潍坊医学院 | 一种含np10抗菌肽的水凝胶及其制备方法和应用 |
CN111228462A (zh) * | 2020-03-10 | 2020-06-05 | 上海交通大学医学院附属新华医院 | 一种抗微生物肽制剂及其制备方法 |
CN112206308A (zh) * | 2020-11-21 | 2021-01-12 | 陕西远志医药生物工程有限公司 | 一种滋养抑菌凝胶及其制备方法 |
-
2021
- 2021-11-24 CN CN202111409344.4A patent/CN114081939B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU903003D0 (en) * | 1990-05-11 | 1990-09-28 | Reanal Finomvegyszergyar | Process for the production of a medicative preparation |
KR20100026910A (ko) * | 2008-08-29 | 2010-03-10 | 한스바이오메드 주식회사 | 서방형 골다공증치료제를 담지한 골충진재 |
CN105031609A (zh) * | 2015-07-22 | 2015-11-11 | 中国药科大学 | 含抗菌肽Cbf-14的消毒剂及其制备和用途 |
CN105497872A (zh) * | 2015-12-23 | 2016-04-20 | 中国药科大学 | 多肽Cbf-14抗真菌感染的医药用途 |
CN106543271A (zh) * | 2016-12-08 | 2017-03-29 | 中国药科大学 | 抗耐药性感染多肽Cbf‑14‑2及其用途 |
CN110169949A (zh) * | 2019-07-01 | 2019-08-27 | 潍坊医学院 | 一种含np10抗菌肽的水凝胶及其制备方法和应用 |
CN111228462A (zh) * | 2020-03-10 | 2020-06-05 | 上海交通大学医学院附属新华医院 | 一种抗微生物肽制剂及其制备方法 |
CN112206308A (zh) * | 2020-11-21 | 2021-01-12 | 陕西远志医药生物工程有限公司 | 一种滋养抑菌凝胶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114081939B (zh) | 2024-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108135745B (zh) | 用于伤口处理的有效新型快速沉积薄膜形成组合物 | |
CN101829320B (zh) | 一种胶原蛋白凝胶及其制备方法 | |
CN107185031B (zh) | 一种具有生物活性的医用敷料及其制备方法 | |
CN107617121B (zh) | 一种皮肤创面生物诱导活性敷料及其制备方法和应用 | |
KR20150013280A (ko) | 박테리아 균막을 제거하기 위한 세아프로제의 용도 | |
Cutting | Wound healing through synergy of hyaluronan and an iodine complex | |
EP2424547A1 (en) | Methods of treatment utilising glucan formulations | |
CN112891615B (zh) | 一种液体创口贴及其制备方法 | |
EP3960190A1 (en) | Use of nocardia rubra cell wall skeleton in treatment of thermal injury | |
US10022394B2 (en) | Antiinfective composition | |
CN115590787B (zh) | 一种用于祛痘和皮肤修复的组合物及其制备方法与应用 | |
CN114081939A (zh) | 一种抗菌肽Cbf-14水凝胶及其制备方法和应用 | |
CN108452370B (zh) | 一种复合型超分子水凝胶及其制备方法 | |
CN110478391A (zh) | 一种具有抑菌作用的茶树油微球及其制备方法 | |
CN112263544B (zh) | 一种盐酸利多卡因凝胶及其制备方法 | |
CN115501246A (zh) | 一种组合物及其制备方法与应用 | |
CN111870590B (zh) | 液体祛痘贴及其制备方法 | |
RU1837870C (ru) | Способ получени суспоэмульсии примицина | |
CN110354078B (zh) | 一种含有血链球菌素的抗白色念珠菌组合物及其制备方法 | |
CN113730641A (zh) | 一种缓释抗菌的敷料及其制备方法 | |
RU2691144C1 (ru) | Комбинированная композиция для лечения инфицированных ран различного генеза | |
CN202191515U (zh) | 一种复合海绵敷料 | |
Revin et al. | Effect of Biocomposites on Bacterial Cellulose-Based Hydrogel and Physiologically Active Compounds on Regeneration Processes in the Skin’s Lipid Phase After Burn Injury | |
CN113143844B (zh) | 一种用于治疗痤疮的聚合物微针贴片及其制备方法 | |
CN111265594A (zh) | 用于修复伤口的药物制剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |